It’s only been 30 days since I pegged TFF Pharmaceuticals, Inc. (TFFP) as a frontrunner to become the next multi-billion-dollar biotech platform. And management’s certainly not wasting any time proving it.

 

After the bell yesterday, the company reported quarterly results, including a $210 million worldwide licensing deal for its Covid-19 drug formulation.

Keep in mind, the single deal is potentially worth more than the company’s current market cap. That’s after shares doubled since our entry.

Truth be told, we’re just getting started here.

In today’s update I share some key takeaways from the call, update my buy up to price and share some thoughts on how I plan to trade around my core position.


This content is reserved for subscribers. To gain immediate access to our 100% independent research on the top tech trends and companies before they become household names, consider subscribing here.

For a limited time only you can use Coupon Code DTR50 to receive 50% off a quarterly or annual subscription.